Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Артериальная гипертензия: защита органов-мишеней vs прогноз. Альтернативный выбор или звенья одной цепи?
Артериальная гипертензия: защита органов-мишеней vs прогноз. Альтернативный выбор или звенья одной цепи?
Привалова Е.В. Артериальная гипертензия: защита органов-мишеней vs прогноз. Альтернативный выбор или звенья одной цепи? Consilium Medicum. 2013; 15 (5): 14–18.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Mourad JJ, Hanon O, Deverre JR et al. Improvement of impaired coronary vasodilator reserve in hypertensive patients by low-dose ACE inhibitor/diuretic therapy: a pilot PET study. JRAAS 2003; 4: 94–5.
2. Barua RS, Ambrose JA, Eales-Reynolds L-J et al. Dysfunctional endothelial nitric oxide biosynthesis in healthy smokers with impaired endothelium-dependent vasodilatation. Circulation 2001; 104: 1905–10.
3. Hamburg NM, Keyes MJ, Larson MG, Vasan RS. Cross-Sectional Relations of Digital Vascular Function to Cardiovascular Risk Factors in the Framingham Heart Study. Circulation 2008; 117: 2467–74.
4. Casino PR, Kilcoyne CM, Quyyumi AA et al. The role of nitric oxide in the endothelium-dependent vasodilation of hypercholesterolemic patients. Circulation 1993; 88: 2541–7.
5. Perticone F, Ceravolo R, Pujia A et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104: 191–6.
6. Диагностика и лечение артериальной гипертензии (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского общества кардиологов). Системные гипертензии 2010; 3: 5–26.
7. Van Vark LC, Bertrand M, Akkerhuis KM et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J 2012; 33 (16): 2088–97.
8. Dominyak and Unger (eds) in Ang II-AT1-Receptor Antagonists. Steinkopff; 1997.
9. Ferrari R. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindorpil. Expert Rev Cardiovasc Ther 2005; 30: 15–29.
10. Ceconi C, Fox KM, Remme WJ et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 2007; 73: 237–46.
11. Anderson AO, Morgan T. Duration of antihypertensive effect of perindopril enalapril and Captopril. Hypertension 1993; 21: 568.
12. Tsoukas G, Anand S, Yang K. CONFIDENCE Investigators. Am J Cardiovasc Drugs 2011; 11 (1): 45–55.
13. Мычка В.Б. Улучшенная форма периндоприла – Престариум А – в лечении больных артериальной гипертонией в различных клинических ситуациях (ПРЕМИЯ). Системные гипертензии 2009; 4: 48–51.
14. Manisty CH, Zambanini A, Parker KH et al. Differences in the magnitude of wave reflection account for differential effects of amlodipine – versus atenolol-based regimens on central blood pressure: an Anglo-Scandinavian cardiac outcome trial substudy. Hypertension 2009; 54: 724–30.
15. Anderson AO, Morgan T. Duration of antihypertensive effect of perindopril enalapril and Captopril. Hypertension 1993; 21: 568.
16. Bots ML, Remme WJ, Luscher TF et al. ACE Inhibition and Endothelial Function: Main Findings of PERFECT, a Sub-Study of the EUROPA Trial. Cardiovasc Drugs Ther 2007; 21 (4): 269–79.
17. Yazawa H, Miyachi M, Furukawa M et al. Angiotensin-converting enzyme inhibition promotes coronary angiogenesis in the failing heart of Dahl salt-sensitive hypertensive rats. J Card Fail 2011; 17 (12): 1041–50.
18. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–8.
19. Patel ADVANCE Collaborative Group. Effect of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829–40.
20. Beckett NS, Peters R, Fletcher AE et al. N Engl J Med 2008; 358:1887–98.
21. Dahlöf B, Sever PS, Poulter NR et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366 (9489): 895–906.
22. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358 (9287): 1033–41.
23. Остроумова О.Д. Исследование эффективности и безопасности периндоприла при лечении больных артериальной гипертонией в стационаре. Сердце. 2006; 3.
24. Brugts JJ, Boersma E, Deckers JW et al. Abstract 5066: The treatment effect of perindopril is consistent in all patients with vascular disease: a combined analysis of three perindopril trials. Circulation 2008; 118: S1138.
25. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364 (9438): 937–52.
26. Недогода С.В., Морозова Т.Е. Возможности коррекции нарушений липидного обмена ингибиторами ангиотензинпревращающего фермента в условиях реальной клинической практики. Cons. Med. 2012; 14 (1): 23–7.
27. Jandrain B et al. Long-term acceptability of perindopril in type II diabetic patients with hypertension. Am J Med 1992; 92: 91–4.
28. Andrejak M et al. A double-blind comparison of perindopril and HCTZ-amiloride in mild to moderate essential hypertension. Fundam Clin Pharmacol 1991; 5: 185–92.
29. Недогода С.В., Чумачок Е.В., Ледяева А.А. и др. Сравнительная эффективность периндоприла и эналаприла у пациентов с артериальной гипертензией. Кардиоваскулярная терапия и профилактика. 2011; 7: 10–7.
30. Мычка В.Б., Масенко В.П., Творогова М.Г. и др. Применение периндоприла у больных мягкой умеренной артериальной гипертензией и метаболическим синдромом. Артериальная гипертензия 2002; 8 (1): 16.
31. Fogari R, Zoppi A, Lazzari P et al. ACE Inhibition But Not Angiotensin II Antagonism Reduces Plasma Fibrinogen and Insulin Resistance in Overweight Hypertensive Patients. J Cardiovasc Pharmacol 1998; 32 (4): 616–20.
32. Savarese G et al. A Meta-Analysis Reporting Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients Without Heart Failure. J Am Col Card 2013; online:1–12.
2. Barua RS, Ambrose JA, Eales-Reynolds L-J et al. Dysfunctional endothelial nitric oxide biosynthesis in healthy smokers with impaired endothelium-dependent vasodilatation. Circulation 2001; 104: 1905–10.
3. Hamburg NM, Keyes MJ, Larson MG, Vasan RS. Cross-Sectional Relations of Digital Vascular Function to Cardiovascular Risk Factors in the Framingham Heart Study. Circulation 2008; 117: 2467–74.
4. Casino PR, Kilcoyne CM, Quyyumi AA et al. The role of nitric oxide in the endothelium-dependent vasodilation of hypercholesterolemic patients. Circulation 1993; 88: 2541–7.
5. Perticone F, Ceravolo R, Pujia A et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104: 191–6.
6. Диагностика и лечение артериальной гипертензии (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского общества кардиологов). Системные гипертензии 2010; 3: 5–26.
7. Van Vark LC, Bertrand M, Akkerhuis KM et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J 2012; 33 (16): 2088–97.
8. Dominyak and Unger (eds) in Ang II-AT1-Receptor Antagonists. Steinkopff; 1997.
9. Ferrari R. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindorpil. Expert Rev Cardiovasc Ther 2005; 30: 15–29.
10. Ceconi C, Fox KM, Remme WJ et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 2007; 73: 237–46.
11. Anderson AO, Morgan T. Duration of antihypertensive effect of perindopril enalapril and Captopril. Hypertension 1993; 21: 568.
12. Tsoukas G, Anand S, Yang K. CONFIDENCE Investigators. Am J Cardiovasc Drugs 2011; 11 (1): 45–55.
13. Мычка В.Б. Улучшенная форма периндоприла – Престариум А – в лечении больных артериальной гипертонией в различных клинических ситуациях (ПРЕМИЯ). Системные гипертензии 2009; 4: 48–51.
14. Manisty CH, Zambanini A, Parker KH et al. Differences in the magnitude of wave reflection account for differential effects of amlodipine – versus atenolol-based regimens on central blood pressure: an Anglo-Scandinavian cardiac outcome trial substudy. Hypertension 2009; 54: 724–30.
15. Anderson AO, Morgan T. Duration of antihypertensive effect of perindopril enalapril and Captopril. Hypertension 1993; 21: 568.
16. Bots ML, Remme WJ, Luscher TF et al. ACE Inhibition and Endothelial Function: Main Findings of PERFECT, a Sub-Study of the EUROPA Trial. Cardiovasc Drugs Ther 2007; 21 (4): 269–79.
17. Yazawa H, Miyachi M, Furukawa M et al. Angiotensin-converting enzyme inhibition promotes coronary angiogenesis in the failing heart of Dahl salt-sensitive hypertensive rats. J Card Fail 2011; 17 (12): 1041–50.
18. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–8.
19. Patel ADVANCE Collaborative Group. Effect of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829–40.
20. Beckett NS, Peters R, Fletcher AE et al. N Engl J Med 2008; 358:1887–98.
21. Dahlöf B, Sever PS, Poulter NR et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366 (9489): 895–906.
22. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358 (9287): 1033–41.
23. Остроумова О.Д. Исследование эффективности и безопасности периндоприла при лечении больных артериальной гипертонией в стационаре. Сердце. 2006; 3.
24. Brugts JJ, Boersma E, Deckers JW et al. Abstract 5066: The treatment effect of perindopril is consistent in all patients with vascular disease: a combined analysis of three perindopril trials. Circulation 2008; 118: S1138.
25. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364 (9438): 937–52.
26. Недогода С.В., Морозова Т.Е. Возможности коррекции нарушений липидного обмена ингибиторами ангиотензинпревращающего фермента в условиях реальной клинической практики. Cons. Med. 2012; 14 (1): 23–7.
27. Jandrain B et al. Long-term acceptability of perindopril in type II diabetic patients with hypertension. Am J Med 1992; 92: 91–4.
28. Andrejak M et al. A double-blind comparison of perindopril and HCTZ-amiloride in mild to moderate essential hypertension. Fundam Clin Pharmacol 1991; 5: 185–92.
29. Недогода С.В., Чумачок Е.В., Ледяева А.А. и др. Сравнительная эффективность периндоприла и эналаприла у пациентов с артериальной гипертензией. Кардиоваскулярная терапия и профилактика. 2011; 7: 10–7.
30. Мычка В.Б., Масенко В.П., Творогова М.Г. и др. Применение периндоприла у больных мягкой умеренной артериальной гипертензией и метаболическим синдромом. Артериальная гипертензия 2002; 8 (1): 16.
31. Fogari R, Zoppi A, Lazzari P et al. ACE Inhibition But Not Angiotensin II Antagonism Reduces Plasma Fibrinogen and Insulin Resistance in Overweight Hypertensive Patients. J Cardiovasc Pharmacol 1998; 32 (4): 616–20.
32. Savarese G et al. A Meta-Analysis Reporting Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients Without Heart Failure. J Am Col Card 2013; online:1–12.
Авторы
Е.В.Привалова
ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ
ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.